Determining the genetic basis of cancer requires comprehensive analyses of large collections
of histopathologically well-classified primary tumours. Here we report the results of a …

Massively parallel DNA sequencing technologies provide an unprecedented ability to
screen entire genomes for genetic changes associated with tumour progression. Here we …

Most patients with acute myeloid leukaemia (AML) die from progressive disease after relapse,
which is associated with clonal evolution at the cytogenetic level 1 , 2 . To determine the …

The Cancer Genome Atlas Network recently cataloged recurrent genomic abnormalities in
glioblastoma multiforme (GBM). We describe a robust gene expression-based molecular …

Early T-cell precursor acute lymphoblastic leukaemia (ETP ALL) is an aggressive malignancy
of unknown genetic basis. We performed whole-genome sequencing of 12 ETP ALL cases …

Genetic alterations in signaling pathways that control cell-cycle progression, apoptosis, and
cell growth are common hallmarks of cancer, but the extent, mechanisms, and co-…

The Cancer Genome Atlas (TCGA) has catalyzed systematic characterization of diverse
genomic alterations underlying human cancers. At this historic junction marking the completion …

We report the results of whole-genome and transcriptome sequencing of tumor and adjacent
normal tissue samples from 17 patients with non-small cell lung carcinoma (NSCLC). We …

Several genetic alterations characteristic of leukemia and lymphoma have been detected in
the blood of individuals without apparent hematological malignancies. The Cancer Genome …

Background The genetic alterations responsible for an adverse outcome in most patients
with acute myeloid leukemia (AML) are unknown. Methods Using massively parallel DNA …